-
New Phase 1 Trial Launches to Study YL217 in Advanced Solid Tumors
A newly registered first-in-human study will evaluate YL217, an investigational peptide-based therapy, in patients with advanced solid tumors, marking an early but hopeful step in oncology research.
-
New Clinical Trial Explores Efgartigimod as Potential Treatment for Guillain-Barré Syndrome
A new study, dubbed GREAT, is investigating whether efgartigimod can offer a safe and effective treatment option for patients battling Guillain-Barré syndrome.
-
New Study to Explore How Retained Natural Insulin Production Supports Diabetes Health
A large new clinical study will investigate how retained endogenous insulin, measured through C-peptide, may benefit quality of life and health outcomes for people living with insulin-treated diabetes.
-
New Phase 2b Trial Launches to Explore Rezpegaldesleukin for Severe Alopecia Areata
A new Phase 2b study is underway to evaluate rezpegaldesleukin, a pegylated interleukin-2 peptide therapy, as a potential treatment for adults with severe to very severe alopecia areata.
-
TwoStep Therapeutics Secures $62.5M Series A and FDA IND Clearance for Novel Peptide-Drug Conjugate
TwoStep Therapeutics has closed an oversubscribed $62.5 million Series A financing round and received FDA clearance to begin clinical trials for its first-in-class peptide-drug conjugate, marking a major step forward for the emerging therapeutic platform.
-
Teitur’s TT-P34 Peptide Shows Promising Early Results for Parkinson’s Disease
Teitur Trophics has reported encouraging early-stage data for TT-P34, an investigational peptide targeting Parkinson’s disease, marking a hopeful step forward in neurodegenerative research.
-
Peptide Therapy Shows Early Promise in Phase I Parkinson’s Trial
A peptide-based treatment has reportedly succeeded in early Phase I testing for Parkinson’s disease, marking an encouraging step toward new therapeutic options for patients.
-
New Clinical Trial Explores Base-Edited Stem Cell Therapy as Potential Cure for WHIM Syndrome
Researchers are launching a trial that uses base-editing technology to correct the CXCR4 gene mutation responsible for WHIM syndrome, offering hope for a one-time curative treatment for this rare immune disorder.
-
New Clinical Trial Explores BMS-986504 Combined with Standard Cancer Therapy for Solid Tumors
A newly launched study is investigating whether BMS-986504, used alongside standard-of-care treatments, can safely help patients with advanced MTAP-deleted solid tumors.
-
New Trial Explores Blood Test to Personalize Immunotherapy After Urothelial Cancer Surgery
A phase II/III trial is testing whether circulating tumor DNA (ctDNA) in the blood can help doctors identify which urothelial cancer patients benefit most from immunotherapy after surgery. The approach could lead to more precise, personalized cancer care.